


PHARMACEUTICAL 2021



GALECTIN THERAPEUTICS INC Rank 194 of 402





PHARMACEUTICAL 2021



GALECTIN THERAPEUTICS INC Rank 194 of 402

The relative strengths and weaknesses of GALECTIN THERAPEUTICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GALECTIN THERAPEUTICS INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 79% points. The greatest weakness of GALECTIN THERAPEUTICS INC is the variable Net Income, reducing the Economic Capital Ratio by 65% points.

The company's Economic Capital Ratio, given in the ranking table, is 104%, being 56% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	29,465
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,399
Liabilities, Non-Current	8.0
Other Assets	135
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-21
Other Revenues	0
Property and Equipment	0
Research and Development	17,976
Selling, General and Administrative Expense	5,468

Output Variable	Value in 1000 USD
Assets	29,600
Liabilities	5,407
Expenses	23,444
Revenues	0
Stockholders Equity	24,193
Net Income	-23,465
Comprehensive Net Income	-23,465
Economic Capital Ratio	104%

